相关实验视频

Updated: Jul 12, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

在青少年和年轻成年人中延迟固体瘤呈现布朗克斯地区的患者

Rachel Offenbacher¹, Sarah Norris¹, David M Loeb¹

¹Division of Pediatric Hematology, Oncology and Cellular Therapy, Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, USA.

Journal of adolescent and young adult oncology

|October 23, 2023

概括

青少年和年轻成人 (AYA) 癌症患者需要更好的过渡支持. 与儿科患者相比,诊断和护理的延迟导致这些人的结果较差.

科学领域:

在瘤学瘤学.
青少年医学青少年医学
医疗保健的转型医疗保健的转型

背景情况:

青少年和年轻人 (AYAs) 在医疗保健过渡期间需要专门的支持.
在AYA (12-17岁) 的儿科实践中,有效的过渡准备过程未得到充分利用.
癌症是AYA患者的主要死亡原因,但他们的结果比儿童癌症患者差.

研究的目的:

突出在AYA瘤学中改善过渡支持的迫切需要.
讨论AYA癌症患者医疗护理的挑战和极端延迟.
展示这些延迟及其影响的案例研究.

主要方法:

对两名年轻成年患者的病例报告分析.
对AYA医疗保健转型和瘤学结果现有文献的审查.
讨论固体瘤的医疗护理的延迟情况.

主要成果:

在提交的案件中,观察到出现医疗护理的显著延迟.
与儿科患者相比,AYA瘤患者面临着独特的挑战,导致结果较差.
目前的过渡准备流程不足以满足AYA的需求.

结论:

迫切需要加强瘤学AYA的过渡支持系统.
解决诊断和护理延迟对于改善AYA癌症结果至关重要.
实施强有力的过渡准备协议对于这个弱势群体至关重要.

关键词:

青少年和年轻成年人 (AYA)延迟癌症呈现的时间.

更多相关视频

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...